ATE267013T1 - Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit - Google Patents

Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit

Info

Publication number
ATE267013T1
ATE267013T1 AT01910051T AT01910051T ATE267013T1 AT E267013 T1 ATE267013 T1 AT E267013T1 AT 01910051 T AT01910051 T AT 01910051T AT 01910051 T AT01910051 T AT 01910051T AT E267013 T1 ATE267013 T1 AT E267013T1
Authority
AT
Austria
Prior art keywords
metabotropic
glutama
dependency
receptor antagonists
tolerance
Prior art date
Application number
AT01910051T
Other languages
English (en)
Inventor
Mauro Corsi
Francois Conquet
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9887294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE267013(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE267013T1 publication Critical patent/ATE267013T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fertilizers (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
AT01910051T 2000-03-09 2001-03-09 Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit ATE267013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0005700.0A GB0005700D0 (en) 2000-03-09 2000-03-09 Therapy
PCT/GB2001/001058 WO2001066113A1 (en) 2000-03-09 2001-03-09 Metabotropic glutamate receptor antagonists for treating tolerance and dependency

Publications (1)

Publication Number Publication Date
ATE267013T1 true ATE267013T1 (de) 2004-06-15

Family

ID=9887294

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01910051T ATE267013T1 (de) 2000-03-09 2001-03-09 Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit

Country Status (17)

Country Link
US (1) US20030195139A1 (de)
EP (1) EP1267869B1 (de)
JP (1) JP2003525902A (de)
CN (1) CN1427720A (de)
AT (1) ATE267013T1 (de)
AU (1) AU783869B2 (de)
CA (1) CA2402341A1 (de)
DE (1) DE60103384T2 (de)
DK (1) DK1267869T3 (de)
ES (1) ES2220727T3 (de)
GB (1) GB0005700D0 (de)
HK (1) HK1053262A1 (de)
NZ (1) NZ521228A (de)
PT (1) PT1267869E (de)
SE (1) SE1267869T5 (de)
TR (1) TR200401862T4 (de)
WO (1) WO2001066113A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102793698A (zh) * 2002-09-10 2012-11-28 诺瓦提斯公司 治疗包括成瘾与抑郁症在内的与mGLU受体相关疾病的mGLU受体拮抗剂
EP1874353A1 (de) 2005-04-05 2008-01-09 Yale University Glutamat-modulierungsmittel bei der behandlung von geisteserkrankungen
US20060264381A1 (en) * 2005-05-05 2006-11-23 Bear Mark F Methods of treating obsessive compulsive disorder
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2007035823A2 (en) * 2005-09-20 2007-03-29 Molecular Neuroimaging, Llc Partial mglur5 antagonists and methods of use thereof
EP1940389A2 (de) 2005-10-21 2008-07-09 Braincells, Inc. Modulation von neurogenese durch pde-hemmung
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2068872A1 (de) 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2578216A1 (de) 2006-11-22 2013-04-10 Seaside Therapeutics, Inc. Verfahren zur Behandlung von Fragilem-X-Syndrom
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
US20130123254A1 (en) * 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
US11878001B2 (en) * 2017-07-31 2024-01-23 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
CA3204360A1 (en) * 2020-12-14 2022-06-23 Novartis Ag Use of mglur5 antagonists for treating gambling disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5543698A (en) * 1994-09-27 1996-08-06 Allen-Bradley Company, Inc. Method and apparatus used with AC motor for detecting unbalance
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
CA2287591A1 (en) * 1997-03-14 1998-09-17 The Johns Hopkins University School Of Medicine Synaptic activation protein compositions and method
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
PT1117403E (pt) * 1998-10-02 2004-04-30 Sibia Neurosciences Inc Antagonistas de mglurs para o tratamento da dor e ansiedade
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
EP1183238A1 (de) * 1999-05-17 2002-03-06 Eli Lilly And Company Metabotropic glutamate rezeptor antagoniste
US6666209B2 (en) * 2001-02-20 2003-12-23 3M Innovative Properties Company Method and system of calibrating air flow in a respirator system

Also Published As

Publication number Publication date
SE1267869T5 (de) 2004-09-07
NZ521228A (en) 2004-04-30
AU3763401A (en) 2001-09-17
EP1267869A1 (de) 2003-01-02
CN1427720A (zh) 2003-07-02
PT1267869E (pt) 2004-10-29
CA2402341A1 (en) 2001-09-13
DE60103384T2 (de) 2005-06-16
DE60103384D1 (de) 2004-06-24
SE1267869T3 (de) 2004-08-31
WO2001066113A1 (en) 2001-09-13
AU783869B2 (en) 2005-12-15
DK1267869T3 (da) 2004-09-20
TR200401862T4 (tr) 2004-10-21
JP2003525902A (ja) 2003-09-02
ES2220727T3 (es) 2004-12-16
HK1053262A1 (en) 2003-10-17
EP1267869B1 (de) 2004-05-19
US20030195139A1 (en) 2003-10-16
GB0005700D0 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
ATE267013T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von toleranz und abhängigkeit
DE69726724D1 (de) Tetrahydropteridine und pyridylpiperazine zur behandlung von neurologischen störungen
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
ATE208210T1 (de) Kombination von proteintyrosin-kinaseinhibitoren und chemischer kastration zur behandlung von prostatakrebs
DE69528475T2 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE316785T1 (de) Jak-3 hemmer zur behandlung von allergischen störungen
DE69913548D1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
DE60206164D1 (de) Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1-naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren
ATE260653T1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60218153D1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE69524623T2 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
DK0422154T3 (da) Terapeutisk anvendelse af 5-HT3-receptorantagonister
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
ATE360425T1 (de) Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
BR0206918A (pt) Uso de iloperidona
DK1366033T3 (da) Kemiske forbindelser
DE60108241D1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
ATE298236T1 (de) Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1267869

Country of ref document: EP

RZN Patent revoked